Latest filing intelligence
REGENERON PHARMACEUTICALS, INC. (REGN)
Read the latest REGN filing as a structured brief: high-signal changes, financial snapshot, and direct links back to the official SEC source.
Filing summary
REGENERON PHARMACEUTICALS, INC. latest filing summary
The filing reads mixed based on revenue and statement momentum.
The latest 10-Q for REGN shows revenue was $3.6B and net income was $727.2M.
Informational only, not investment advice. Verify material conclusions in the official filing before acting on any summary.
Key changes
What changed and why it matters
- Revenue moved to $3.6B from $3.8B (-4.0% vs prior).
- Net income moved to $727.2M from $1.5B (-50.2% vs prior).
- Diluted EPS moved to $6.75 from $13.62 (-50.4% vs prior).
What matters now
Mixed-to-negative read
Research note
Research note
This company page should work as a first research note, not just a label applied to a filing. The goal is to explain what changed, why that change matters, and which parts of the source filing deserve a slower read.
Use the latest filing summary with the comparison blocks and statement sections. The important question is whether the quarter or year changed the underlying business read, not whether one headline metric looked better than expected.
A good next step is to verify the management framing in the primary source and keep a short watchlist of the two or three metrics most likely to matter in the next report.
What to watch
Company-specific checkpoints for the next filing
- Revenue quality and the main profit driver
- Margin durability
- Cash generation and liquidity
- One company-specific operational risk worth monitoring
Company context
Why REGN stays in the tracked universe
REGENERON PHARMACEUTICALS, INC. is tracked in Quantfil because it sits inside Healthcare / Biotechnology and regularly produces filings that matter to cross-sector read-throughs. The latest 10-Q is being used as the current anchor report, while the next earnings date is not currently scheduled in the tracked calendar feed. REGENERON PHARMACEUTICALS, INC. filing dashboard built from SEC EDGAR company facts and recent periodic filings.
REGENERON PHARMACEUTICALS, INC. (REGN) is being read through the latest 10-Q first. The current question is whether the reported change meaningfully shifts the read on the business relative to other names in Healthcare. REGENERON PHARMACEUTICALS, INC. filing dashboard built from SEC EDGAR company facts and recent periodic filings. Current filing is compared against the nearest prior comparable period detected from SEC company facts.
Verification notes
What to focus on next
- Confirm the 10-Q filing date, report period, and SEC source link before comparing figures.
- Check whether operating income and cash flow support the top-line narrative, not just the revenue figure.
- Read the statement visuals and comparison cards together so the filing is not judged on one metric in isolation.
- Read the official 10-Q source if a risk-factor change or accounting note could alter the conclusion.
- Treat the summary as a prioritization tool first and an investment conclusion second.
Common mistake
A common mistake is stopping at management's framing. Always compare the narrative with the statement lines, footnotes, and the prior filing before deciding what changed.
Quantfil pages are built from pre-generated public-company data and daily refreshed static assets. They are designed to accelerate the first read, not replace the underlying filing. Next earnings timing is not currently available for this symbol in the tracked public calendar feed.
Financial snapshot
Latest reported figures
Trend section
Recent revenue trend
Current versus prior
How the latest report differs from the previous filing
Current $3.6B · Prior $3.8B
Current $727.2M · Prior $1.5B
Current $6.75 · Prior $13.62
Current $3.0B · Prior $3.1B
Current $31.4B · Prior $31.3B
Current $1.1B · Prior $1.0B
Related links
Move through the research workflow
Related reading